文献速递骨显像与常规 SPECT核素与放射性配体治疗

68Ga-DOTA-伊班膦酸PET/CT意外发现双侧泪腺及唾液腺摄取

Unexpected Bilateral Lacrimal and Salivary Gland Uptake of 68 Ga-DOTA-Ibandronic Acid on PET/CT.
PubMed 文献 · Clin Nucl Med · 2026-06-15

本文报道一例肺腺癌多发骨转移患者行68Ga-DOTA-伊班膦酸PET/CT显像,除转移性骨病灶摄取增高外,双侧泪腺及唾液腺亦见意外摄取增高。该发现提示在启动177Lu-DOTA-伊班膦酸放射性药物治疗前,应评估泪腺和唾液腺的潜在辐射暴露。

要点

  • 68Ga-DOTA-IBA为新型骨显像PET示踪剂,用于恶性肿瘤骨转移诊断及177Lu-DOTA-IBA靶向治疗指导。
  • 本例肺腺癌多发骨转移患者中,转移性骨病灶及双侧泪腺、唾液腺均见68Ga-DOTA-IBA摄取增高。
  • 启动177Lu-DOTA-IBA治疗前需评估泪腺和唾液腺的潜在辐射暴露。

核心结论

  • 肺腺癌多发骨转移患者行68Ga-DOTA-IBA PET/CT时,除转移性骨病灶摄取增高外,双侧泪腺及唾液腺亦出现意外摄取增高。
  • 该发现提示在启动177Lu-DOTA-IBA放射性药物治疗前应评估泪腺和唾液腺的潜在辐射暴露。

研究设计与样本

  • 单例临床病例报告,患者为肺腺癌伴多发骨转移,行68Ga-DOTA-IBA PET/CT显像。

主要发现

  • 转移性骨病灶中68Ga-DOTA-IBA摄取增高。
  • 双侧泪腺和唾液腺也出现意外的68Ga-DOTA-IBA摄取增高。

临床怎么用

  • 在启动177Lu-DOTA-IBA放射性药物治疗前,应关注并评估泪腺和唾液腺的潜在辐射暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68 Ga-DOTA-ibandronic acid (IBA) represents a novel positron emission tomography (PET) tracer for bone imaging, primarily employed in the diagnosis of malignant tumor metastases and the guidance of subsequent 177 Lu - DOTA - IBA targeted radionuclide therapy. In a clinical case involving a patient with lung adenocarcinoma and multiple osseous metastases, increased 68 Ga-DOTA-IBA uptake was observed in the metastatic bone lesions. Unexpectedly, increased uptake was also noted in the bilateral lacrimal and salivary glands. This finding underscores the importance of evaluating potential radiation exposure to lacrimal and salivary glands before initiating 177 Lu-DOTA-IBA-based radiopharmaceutical therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Luo H, Tang R, Pu J, et al. Unexpected Bilateral Lacrimal and Salivary Gland Uptake of 68 Ga-DOTA-Ibandronic Acid on PET/CT. Clin Nucl Med. 2026. PMID: 42341194. doi:10.1097/RLU.0000000000006575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。